Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (560)	3/5/2001 9:00:46 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

The Merck-Sibia deal is a bragging point?? Grrrrrrrrr............... Monday March 5, 8:35 am Eastern Time Press Release SOURCE: Corvas International, Inc. Stephen Keane Joins Corvas as Vice President, Corporate Development SAN DIEGO, March 5 /PRNewswire/ -- Corvas International, Inc. (Nasdaq: CVAS - news) announced today that Stephen F. Keane has been appointed Vice President, Corporate Development. In this newly created position, Mr. Keane will be responsible for corporate strategy and business development activities in support of Corvas' cardiovascular and cancer programs. Mr. Keane brings over 16 years of business experience in the biotechnology industry, during which he has negotiated numerous strategic corporate alliances, established joint ventures, assisted in public and private financings, and contributed to successful product development, approval and launch. Mr. Keane held senior corporate development positions with Epimmune, Inc., SIBIA Neurosciences, Inc. and Molecular Biosystems, Inc. In these positions, he was responsible for negotiating many significant alliances including licenses, distribution agreements, technology acquisitions, and research agreements with large pharmaceutical companies and government agencies. He was the principle negotiator for the acquisition of SIBIA by Merck & Co. ``It is a pleasure to welcome Stephen as a key member of Corvas' management team,'' stated Randall E. Woods, President and Chief Executive Officer of Corvas. ``Stephen brings a wealth of experience in successful negotiations with large pharmaceutical companies which will be an important factor in forming corporate collaborations and in-licensing or acquiring complementary products, technologies or companies,'' added Mr. Woods. Corvas International, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutics that address large markets, including cardiovascular disease, stroke and cancer. This press release, including the statements made by Mr. Woods, other statements that are not historical facts and the Company's web site at www.corvas.com, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could vary materially from those described as a result of a number of factors, including a risk that Corvas will not retain the services of Mr. Keane or other key employees and those set forth in Corvas' Annual Report on Form 10-K and any subsequent SEC filings. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. SOURCE: Corvas International, Inc.